Business Wire

KEMRI and NEC Announce Trials on Biometric-based Vaccination Management System for Newborn Children in Kenya

Share

The Kenya Medical Research Institute (KEMRI), NEC Corporation (NEC; TOKYO: 6701) and Nagasaki University have developed a digital biometric-based vaccination management system for newborn children in Kenya. Validation of this system is taking place through KEMRI with a clinical trial that began in September 2022 at the Kinango Sub-County Hospital in Kwale.

The digital system being provided by NEC, a leader in the integration of IT and network technologies, and KEMRI, one of Africa’s leading research Institutions, will effectively and seamlessly manage vaccination history and scheduling using fingerprint identification for newborn children and voice recognition for caregivers.

This technology marks the first time that biometric identification is being used at a hospital to identify newborn children at the time of vaccination, including those immediately after delivery (*1).

In terms of background, many children around the world continue to lose their lives at a very young age. In 2020 alone, approximately 5 million children died before reaching their fifth birthday. Furthermore, about half of these children under the age of five, or 2.4 million children, passed away within 28 days of birth, with many of the deaths considered preventable (*2).

Meanwhile, in some regions in the world, the use of digital technology has not advanced due to delays in the development of electricity and telecommunications infrastructure. In these regions, medical services may only be recorded by hand. In such cases, health care providers cannot easily ascertain which medical services are needed for the caregivers and children who visit their hospitals, which is one of the factors hindering efforts to ensure that children receive the vaccinations they need.

The new technology combines fingerprint identification for children and voice recognition for caregivers to confirm not only their identity, but also to reliably manage vaccination histories and schedules, thereby promoting the implementation of appropriate vaccinations for newborns and children during the first 24 months of life. Going forward, demonstration tests that network multiple hospitals will begin, aiming for full-scale introduction throughout Kenya by the end of 2023, and more international deployment in the future.

Voice and fingerprint data will be deleted after completion of the trial.

Link to press release:
https://www.nec.com/en/press/202302/global_20230207_01.html

Notes:

(*1) NEC research as of February 7, 2023
(*2) Source: Levels and trends in child mortality, Report 2021, UN-IGME
https://data.unicef.org/resources/levels-and-trends-in-child-mortality/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Joseph Jasper
j-jasper(at)nec.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rimini Street Announces Fiscal Second Quarter 2025 Financial and Operating Results31.7.2025 23:01:00 EEST | Press release

Rimini Street, Inc., (the “Company”) (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal second quarter ended June 30, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250731791846/en/ Rimini Street Announces Fiscal Second Quarter 2025 Financial and Operating Results Select Second Quarter 2025 Financial Results Revenue was $104.1 million for the 2025 second quarter, an increase of 1.0% compared to $103.1 million for the same period last year. U.S. revenue was $49.2 million for the 2025 second quarter, a decrease of 4.5% compared to $51.5 million for the same period last year. International revenue was $55.0 million for the 2025 second quarter, an increase of 6.4% compared to $51.7 million for the same period last year. Subscription revenue was $98.5 mil

Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development31.7.2025 21:56:00 EEST | Press release

Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a strategic collaboration aimed at enhancing preclinical research and accelerating the path from discovery to clinical trials. This partnership combines Altasciences’ comprehensive early-phase drug development capabilities with VoxCell’s cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment. By integrating VoxCell’s high-resolution 3D bioprinted tissue platforms into Altasciences’ discovery and preclinical services, both companies aim to reduce R&D timelines and increase the success rate of investigational therapies. “We’re proud to partner with VoxCell BioInnovation to bring next-generation tissue modeling into the early stages of drug development,” said Steve Mason, Co-Chief Operating Officer at Altasciences. “This collaboration aligns with

GEA Raises Forecast for Fiscal Year 2025 and Provides Positive Outlook31.7.2025 20:40:00 EEST | Press release

Due to a very positive operating performance in the first 6 months and expectations for the remainder of the financial year 2025, GEA Group Aktiengesellschaft is raising all guidance parameters based on preliminary figures as follows: Organic sales growth 2 to 4 percent (previously 1 to 4 percent), EBITDA-margin before restructuring expenses 16.2 to 16.4 percent (previously 15.6 to 16.0 percent) and ROCE 34 to 38 percent (previously 30 to 35 percent). The company will publish its complete statement for the 2nd quarter (half-year financial report) on August 7, 2025. “Our positive development continues. The additional improvements are broad-based, supported by a favorable order situation as well as margin improvements and efficiency gains across the Group. Once again, we are thus demonstrating our strength in executing on our plans,” said GEA CEO Stefan Klebert. Alongside improving the profitability indicators EBITDA margin before restructuring expenses and ROCE, GEA also increased order

Global Technology Leaders Adopt Access Advance's Video Distribution Patent Pool31.7.2025 19:58:00 EEST | Press release

A diverse group of global companies across the video ecosystem has joined Access Advance's Video Distribution Patent ("VDP") Pool and is now sharing why they selected this pool. Positioned as a balanced, transparent, and comprehensive video codec licensing solution for the video streaming industry, the pool brings together major patent holders, video platform operators, and stakeholders in the consumer device market in an effort to help the industry navigate the complex licensing challenges in the rapidly evolving video distribution markets. The VDP Pool has attracted an unprecedented list of industry leaders as both licensors and licensees, including ByteDance, Dolby, JVC Kenwood, Kuaishou, HFI (an affiliate of MediaTek), Mitsubishi, OPPO, Philips, Tencent, and other major technology companies. This broad participation spans the entire video ecosystem, from content platforms serving billions of users to semiconductor companies powering video devices worldwide. Collaborative Framework

Interactive Brokers Launches Version 1.0 of IBKR Desktop, Delivering a Comprehensive Trading Experience in One Platform31.7.2025 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the official launch of Version 1.0 of IBKR Desktop, a next-generation trading platform that balances simplicity with advanced functionality. This release follows two years of iterative beta development and introduces a fully featured desktop trading experience for investors worldwide. IBKR Desktop is designed to serve as a primary trading platform for both retail and professional clients. It combines all key trading workflow components, including discovery, analysis, execution, and portfolio management, in a powerful and intuitive interface. “We built IBKR Desktop to meet the needs of all investors, from experienced traders to those just getting started,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “With this release, we are delivering a platform that is easy to use yet rich in features, allowing users to start their trading journey with this platform and easily move to more

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye